Lingyan Li
Overview
Explore the profile of Lingyan Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
1284
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li L, Wen J, Liang J, Cheng X, Yao J, Gao Y, et al.
Chemistry
. 2025 Feb;
:e202404569.
PMID: 40017416
Heteroatom doping and structural modification can significantly improve the electrochemical properties of carbon materials, but it is difficult to achieve synchronous control of the two. To this end, N-doped porous...
2.
A case report of an M protein-negative patient with POEMS syndrome associated with renal involvement
Liu W, Zhou Y, Li L, Zhang F, Xiong Z, Hou S
BMC Nephrol
. 2024 Dec;
25(1):472.
PMID: 39719549
Background: POEMS syndrome with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes is an uncommon plasma cell paraneoplastic syndrome involving multiple system. It is relatively rare in clinical practice, and...
3.
Yu B, Liu W, Hu Y, Huang Y, Dai Q, Yang Y, et al.
BMC Pulm Med
. 2024 Dec;
24(1):627.
PMID: 39707266
Background: Cardiovascular diseases are among the most common and clinically significant comorbidities of chronic obstructive pulmonary disease (COPD). Exercise has been shown to reduce the risk of cardiovascular diseases, and...
4.
Cheng X, Zhang L, Li L, Wu H, Zheng J, Sun J, et al.
Chemistry
. 2024 Dec;
31(4):e202403439.
PMID: 39639803
In order to improve the electrochemical performance of NiCo-based layered double hydroxide (NiCoLDH), the synthesis of low-crystallinity NiCoLDH was induced by the adsorption of glucose and NiCoLDH. The results showed...
5.
Bi F, Dong J, Jin C, Niu Z, Yang W, He Y, et al.
J Hematol Oncol
. 2024 Nov;
17(1):109.
PMID: 39529169
Though several anti-PD-1/PD-L1 antibodies approved for monotherapy in microsatellite instability-high or mismatch repair-deficient unresectable/metastatic solid tumors, novel immunotherapy with better anti-tumor activity is needed in clinic. In this single-arm, multicenter,...
6.
Wei Z, Xia B, Jiang L, Zhu H, Li L, Wang L, et al.
Front Psychiatry
. 2024 Nov;
15:1490171.
PMID: 39502294
Objective: To assess occupational burnout conditions and work-related factors among frontline medical staff during the COVID-19 pandemic and analyse the relationships among these factors utilizing the job demands-resources (JD-R) model...
7.
Cheng X, Zhang L, Li L, Li X, Wu H, Zheng J, et al.
Chemistry
. 2024 Oct;
30(69):e202402597.
PMID: 39355930
Biomass carbon has the advantages of wide source, low cost and environmental protection, and has been widely used in the field of electrochemical energy storage. In this work, N and...
8.
Zhu Y, Li L, Wang W, Liu X, Zhang M, Chen X, et al.
Infect Drug Resist
. 2024 Sep;
17:4067-4078.
PMID: 39309070
Introduction: The Omicron variant is the present predominant COVID-19 strain worldwide. Accurate mortality prediction can facilitate risk stratification and targeted therapies. The study aimed to evaluate the feasibility of the...
9.
Xiong J, Ouyang W, Yang M, Gao Z, Zhou H, Lou H, et al.
Adv Ther
. 2024 Sep;
41(11):4153-4171.
PMID: 39276185
Introduction: Iparomlimab (QL1604) is a humanized immunoglobulin G4 mAb against programmed cell death protein 1 (PD-1). Here, we report the preliminary efficacy, safety, pharmacokinetics, and immunogenicity of iparomlimab in patients...
10.
Chang Y, Liang Y, Wu H, Li L, Yang B, Jiang L, et al.
J Appl Clin Med Phys
. 2024 Jul;
25(10):e14462.
PMID: 39072895
Purpose: Anatomical and other changes during radiotherapy will cause inaccuracy of dose distributions, therefore the expectation for online adaptive radiation therapy (ART) is high in effectively reducing uncertainties due to...